Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data-Reference-Cited by-同舟云学术

Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data

Published:2020-09-03 Issue:6 Volume:112 Page:807-816
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Matsuda Shinichiro,Suzuki Ritsuro,Takahashi Tsutomu,Suehiro Youko,Tomita Naoto,Izutsu Koji,Fukuhara Noriko,Imaizumi Yoshitaka,Shimada Kazuyuki,Nakazato Tomonori,Yoshida Isao,Miyazaki Kana,Yamaguchi Motoko,Suzumiya Junji

Funder

Japan Agency for Medical Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-020-02984-w.pdf

Reference37 articles.

1. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484–93.

2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

3. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42.

4. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000;18:3633–42.

5. Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991;49:696–703.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study;Health Science Reports;2023-11-28

2. Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4068 patients;Haematologica;2023-08-31

3. Use of benzodiazepines is the risk factor for infection in patients aged 80 years or older with diffuse large B-cell lymphoma: A single-institution retrospective study;PLOS ONE;2022-06-10

4. A case of complete atrioventricular block associated with primary cardiac lymphoma reversed without cardiac pacemaker implantation;Journal of International Medical Research;2022-04

5. Baseline and progressive adipopenia in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features are associated with worse clinical outcomes;Leukemia & Lymphoma;2022-02-02